Ra Chem Pharma Profile
Key Indicators
- Authorised Capital ₹ 29.10 Cr
as on 10-07-2023
- Paid Up Capital ₹ 8.50 Cr
as on 10-07-2023
- Company Age 28 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 80.00 Cr
as on 10-07-2023
- Satisfied Charges ₹ 802.55 Cr
as on 10-07-2023
- Revenue 14.75%
(FY 2021)
- Profit -5.81%
(FY 2021)
- Ebitda -10.73%
(FY 2021)
- Net Worth 24.87%
(FY 2021)
- Total Assets 15.81%
(FY 2021)
About Ra Chem Pharma
- CIN/LLPIN
U24110TG1996PLC022816
- Company No.
022816
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Jan 1996
- Date of AGM
29 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc-Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ra Chem Pharma Limited offer?
Ra Chem Pharma Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services, Anti Infective API, Streptomycin Sulfate API, Chemical Compound, Solar Panels, Solar Module, Diclofenac, Diclofenac Paracetamol and Chlorzoxazone Tablet, Pharma Ingredients & Raw Materials.
Who are the key members and board of directors at Ra Chem Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatanaga Raju  | Managing Director | 27-Oct-2020 | Current |
| Praneeth Gunda | Company Secretary | 07-Sep-2017 | Current |
| Jayant Manmadkar | CFO(Kmp) | 16-Jul-2021 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pankaj Patwari | Director | 27-Oct-2020 | Current |
| Anil Chanana | Additional Director | 15-Dec-2021 | Current |
| Shweta Jalan | Director | 27-Oct-2020 | Current |
| Bhaskar Iyer | Director | 27-Oct-2020 | Current |
| Abhijit Mukherjee | Director | 27-Oct-2020 | Current |
Financial Performance and Corporate Structure Insights of Ra Chem Pharma.
Ra Chem Pharma Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 14.75% increase. The company also saw a slight decrease in profitability, with a 5.81% decrease in profit. The company's net worth Soared by an impressive increase of 24.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ra Chem Pharma?
In 2021, Ra Chem Pharma had a promoter holding of 74.00% and a public holding of 26.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 15 Sep 2022 | ₹80.00 Cr | Open |
Axis Bank Limited Creation Date: 13 Mar 2020 | ₹52.00 Cr | Satisfied |
Indusind Bank Ltd. Creation Date: 30 Jan 2018 | ₹10.60 Cr | Satisfied |
How Many Employees Work at Ra Chem Pharma?
Ra Chem Pharma has a workforce of 1138 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ra Chem Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ra Chem Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
